ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:4AB - US00287Y1091 - Common Stock
189.8 EUR
-4.8 (-2.47%)
Overall 4AB gets a fundamental rating of 5 out of 10. We evaluated 4AB against 83 industry peers in the Biotechnology industry. While 4AB is still in line with the averages on profitability rating, there are concerns on its financial health. 4AB has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
4AB had positive earnings in the past year.
In the past year 4AB had a positive cash flow from operations.
In the past 5 years 4AB has always been profitable.
In the past 5 years 4AB always reported a positive cash flow from operatings.
1.2 Ratios
4AB's Return On Assets of 1.75% is fine compared to the rest of the industry. 4AB outperforms 73.49% of its industry peers.
4AB has a Return On Invested Capital of 15.64%. This is amongst the best in the industry. 4AB outperforms 92.77% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 4AB is in line with the industry average of 12.74%.
The last Return On Invested Capital (15.64%) for 4AB is above the 3 year average (13.67%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROIC | 15.64% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
With a decent Profit Margin value of 3.94%, 4AB is doing good in the industry, outperforming 77.11% of the companies in the same industry.
In the last couple of years the Profit Margin of 4AB has declined.
4AB has a better Operating Margin (33.05%) than 89.16% of its industry peers.
In the last couple of years the Operating Margin of 4AB has declined.
Looking at the Gross Margin, with a value of 71.16%, 4AB is in the better half of the industry, outperforming 60.24% of the companies in the same industry.
4AB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 4AB is creating value.
The number of shares outstanding for 4AB remains at a similar level compared to 1 year ago.
The number of shares outstanding for 4AB has been increased compared to 5 years ago.
Compared to 1 year ago, 4AB has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.40 indicates that 4AB is not a great score, but indicates only limited risk for bankruptcy at the moment.
4AB has a better Altman-Z score (2.40) than 71.08% of its industry peers.
4AB has a debt to FCF ratio of 3.49. This is a good value and a sign of high solvency as 4AB would need 3.49 years to pay back of all of its debts.
4AB has a Debt to FCF ratio of 3.49. This is amongst the best in the industry. 4AB outperforms 80.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Altman-Z | 2.4 |
ROIC/WACC1.88
WACC8.33%
2.3 Liquidity
4AB has a Current Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
4AB's Current ratio of 0.72 is on the low side compared to the rest of the industry. 4AB is outperformed by 77.11% of its industry peers.
4AB has a Quick Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.60, 4AB is doing worse than 77.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
The earnings per share for 4AB have decreased strongly by -12.09% in the last year.
4AB shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.51% yearly.
The Revenue has been growing slightly by 7.40% in the past year.
Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
4AB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.67% yearly.
The Revenue is expected to grow by 7.50% on average over the next years.
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.67%
Revenue Next Year8.74%
Revenue Next 2Y9.13%
Revenue Next 3Y8.7%
Revenue Next 5Y7.5%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 23.37 indicates a rather expensive valuation of 4AB.
Based on the Price/Earnings ratio, 4AB is valued cheaper than 80.72% of the companies in the same industry.
When comparing the Price/Earnings ratio of 4AB to the average of the S&P500 Index (27.19), we can say 4AB is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 15.20, the valuation of 4AB can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 4AB indicates a rather cheap valuation: 4AB is cheaper than 89.16% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.92, 4AB is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.37 | ||
| Fwd PE | 15.2 |
4.2 Price Multiples
79.52% of the companies in the same industry are more expensive than 4AB, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, 4AB is valued cheaply inside the industry as 86.75% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.84 | ||
| EV/EBITDA | 16.08 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of 4AB may justify a higher PE ratio.
A more expensive valuation may be justified as 4AB's earnings are expected to grow with 16.87% in the coming years.
PEG (NY)3.2
PEG (5Y)9.31
EPS Next 2Y19.85%
EPS Next 3Y16.87%
5. Dividend
5.1 Amount
4AB has a Yearly Dividend Yield of 3.09%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 0.76, 4AB pays a better dividend. On top of this 4AB pays more dividend than 97.59% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.92, 4AB pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.09% |
5.2 History
On average, the dividend of 4AB grows each year by 7.72%, which is quite nice.
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
4AB pays out 489.69% of its income as dividend. This is not a sustainable payout ratio.
4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP489.69%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
FRA:4AB (1/9/2026, 7:00:00 PM)
189.8
-4.8 (-2.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners75.04%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap335.45B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts78.38
Price Target212.95 (12.2%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.09% |
Yearly Dividend5.36
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)-0.14%
PT rev (3m)8.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.79%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-11.46%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)0.47%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.37 | ||
| Fwd PE | 15.2 | ||
| P/S | 6.55 | ||
| P/FCF | 19.84 | ||
| P/OCF | 18.72 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.08 |
EPS(TTM)8.12
EY4.28%
EPS(NY)12.49
Fwd EY6.58%
FCF(TTM)9.57
FCFY5.04%
OCF(TTM)10.14
OCFY5.34%
SpS28.99
BVpS-1.28
TBVpS-45
PEG (NY)3.2
PEG (5Y)9.31
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROCE | 20.86% | ||
| ROIC | 15.64% | ||
| ROICexc | 16.59% | ||
| ROICexgc | 572.43% | ||
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% | ||
| FCFM | 33% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 14.25% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 838.33% | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 2.4 |
F-Score7
WACC8.33%
ROIC/WACC1.88
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.67%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.74%
Revenue Next 2Y9.13%
Revenue Next 3Y8.7%
Revenue Next 5Y7.5%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.3%
EBIT Next 3Y15.61%
EBIT Next 5Y10.95%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status for 4AB stock?
ChartMill assigns a valuation rating of 5 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for 4AB stock?
The financial health rating of ABBVIE INC (4AB.DE) is 3 / 10.
How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?
The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 489.69%.